From Beaverton, Oregon, USA:
My friend is a senior citizen who has been treated for type 2 diabetes for many years. Her doctor put her on Amaryl [glimepiride, a pill for Type 2 diabetes] 5mg per day a little over a year ago. Within approximately two months, she had an episode during which she nearly swallowed her tongue. An emergency room doctor diagnosed her as having a reaction to the Amaryl and prescribed her earlier medicine. She has now lost control of the muscles in her mouth so that she has an involuntary reaction with her tongue. Whenever she places food in her mouth, her tongue tries to force it back out. Her tongue goes in and out of her mouth involuntarily at times and she slurs her speech. She has not taken Amaryl for about a year, but the problem has not gone away. Is this a common reaction to Amaryl? Is there a prescribed treatment that might help her regain control of her muscles?
No, this is not a normal reaction to the Amaryl, and I suspect that your friend did not have a reaction to the Amaryl directly, although she may have had a severe hypoglycemic "low blood sugar" episode. It could also be that she had another type of neurological event that caused a seizure. People with diabetes are two to three more likely to suffer a stroke than the general population. It sounds like she is having continued effects from this event, and I strongly encourage you to help your friend get evaluated by her physician and possibly get referred to a neurologist.
Original posting 29 Dec 2000
Posted to Medications: Pills for Diabetes
Last Updated: Tuesday April 06, 2010 15:09:18
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents.
© Children with Diabetes, Inc. 1995-2016. Comments and Feedback.